ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 881

Cardiopulmonary Involvement in Takayasu Arteritis

David Brennan1, Kenneth J. Warrington2, Jean Schmidt3, Cynthia S. Crowson4 and Matthew J. Koster5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France, 4Health Sciences Research, Mayo Clinic, Rochester, MN, 5Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, takayasu arteritis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  

Takayasu arteritis (TAK) is an inflammatory large-vessel vasculitis of unknown etiology affecting the proximal aorta and its primary branches. Heart disease is a major cause of death in patients with TAK but studies evaluating coronary/pulmonary artery involvement and myocardial dysfunction in this population have been limited.

Methods:  

A retrospective cohort of patients with newly diagnosed TAK from 1984 to 2009 was assembled. All patients included met 1990 American College of Rheumatology classification criteria for TAK. Demographics, baseline disease characteristics, relapse events, surgeries and mortality were abstracted from direct medical record review. Angiograms (invasive and non-invasive), echocardiograms, nuclear medicine scans, and electrocardiograms (ECG) were reviewed for evidence of CP involvement. For the purpose of this study, CP abnormalities were defined as coronary or pulmonary artery vasculitis, left ventricular (LV) dysfunction, left atrial (LA) enlargement, moderate-severe valvular disease, pulmonary arterial hypertension (PAH), regional wall hypokinesis/akinesis, LV hypertrophy or persistent ECG axis deviation. Cox models with time-dependent covariates were used to assess the association between CP involvement and outcomes.

Results:

A total of 117 patients with TAK were identified. Forty-five (38%) patients had at least one objective CP abnormality observed within 6 months of TAK diagnosis. Age at diagnosis was higher in those with CP involvement than those without (34.6 vs 30.1 yrs, respectively; p=0.04). Baseline characteristics and symptoms were similar, except shortness of breath, which was more frequently observed at TAK diagnosis in patients with CP involvement compared to those without (53% vs 21%, respectively; p=0.001). PAH was identified in 7, pulmonary arteritis in 9, coronary arteritis in 3, aortic valve insufficiency in 10 (6 moderate, 4 severe), LV systolic heart failure in 4, LV enlargement in 17, and LA atrial enlargement in 17 patients. Seventy-seven patients had at least 1 year of follow-up [median (IQR): 5.5 (2.9-10.1) years]. Of these 77 patients, 44 had at least one vascular or valvular surgery during the follow-up period. Composite CP involvement was not associated with risk of first surgery [Hazard ratio (95% CI): 1.21 (0.64-2.30); p=0.56]. However, PAH on echocardiogram was significantly associated with risk of first surgery [HR (95% CI): 12.9 (1.86-89.14); p=0.01]. During follow-up 7 patients died. CP involvement was not significantly associated with mortality [HR (95% CI): 2.51 (0.45-14.02); p=0.29].

Conclusion:  

Cardiopulmonary abnormalities in TAK are common. In this population, the presence of PAH predicted a 13-fold increased risk for vascular or valvular surgery. In this cohort, the presence of CP involvement did not increase mortality.


Disclosure: D. Brennan, None; K. J. Warrington, None; J. Schmidt, None; C. S. Crowson, None; M. J. Koster, None.

To cite this abstract in AMA style:

Brennan D, Warrington KJ, Schmidt J, Crowson CS, Koster MJ. Cardiopulmonary Involvement in Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cardiopulmonary-involvement-in-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiopulmonary-involvement-in-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology